ADORA2A and ovarian cancer: This might further explain the very potent effects observed with anti-CD73 and anti-ADORA2A directed strategies in animal tumor models [8, 10, 55] – and it could show a new strategy to interfere with MDSC, TAM and their tumor-promoting role in ovarian cancer.